Literature DB >> 29571438

Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.

Anne-Els van de Logt1, Karine Dahan2, Alexandra Rousseau3, Renate van der Molen4, Hanna Debiec5, Pierre Ronco6, Jack Wetzels7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29571438     DOI： 10.1016/j.kint.2017.12.019

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  21 in total

1.  Nephro Update Europe 2018.

Authors:  Nina Kesel
Journal:  Kidney Dis (Basel)       Date:  2019-04-26

2.  Antibodies Against M-Type Phospholipase Receptor and Prediction of Outcome in Membranous Nephropathy: We are Not There Yet.

Authors:  Jack F M Wetzels
Journal:  Am J Nephrol       Date:  2018-11-23       Impact factor: 3.754

3.  Management of Membranous Nephropathy after MENTOR.

Authors:  Claire Trivin-Avillach; Laurence H Beck
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-18       Impact factor: 8.237

4.  Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY.

Authors:  Nattawat Klomjit; Ladan Zand
Journal:  Kidney360       Date:  2021-04-19

5.  Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CON.

Authors:  Anne-Els van de Logt; Jack F Wetzels
Journal:  Kidney360       Date:  2021-04-19

6.  Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Authors:  Francesco Scolari; Elisa Delbarba; Domenico Santoro; Loreto Gesualdo; Antonello Pani; Nadia Dallera; Laila-Yasmin Mani; Marisa Santostefano; Sandro Feriozzi; Marco Quaglia; Giuliano Boscutti; Angelo Ferrantelli; Carmelita Marcantoni; Patrizia Passerini; Riccardo Magistroni; Federico Alberici; Gian Marco Ghiggeri; Claudio Ponticelli; Pietro Ravani
Journal:  J Am Soc Nephrol       Date:  2021-03-01       Impact factor: 10.121

Review 7.  A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy.

Authors:  Pingna Zhang; Weijun Huang; Qiyan Zheng; Jingyi Tang; Zhaocheng Dong; Yuhua Jiang; Yuning Liu; Weijing Liu
Journal:  J Immunol Res       Date:  2021-07-14       Impact factor: 4.818

8.  Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.

Authors:  Aikaterini Nikolopoulou; Marie Condon; Tabitha Turner-Stokes; H Terence Cook; Neill Duncan; Jack W Galliford; Jeremy B Levy; Liz Lightstone; Charles D Pusey; Candice Roufosse; Thomas D Cairns; Megan E Griffith
Journal:  BMC Nephrol       Date:  2019-09-06       Impact factor: 2.388

9.  Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.

Authors:  Yaling Guo; Xueping Wu; Lei Liu; Haifeng Zhang; Lijuan Yang; Weidong Chen
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

10.  Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.

Authors:  Nicolas Hanset; Emmanuel Esteve; Emmanuelle Plaisier; Catherine Johanet; Pierre-Antoine Michel; Jean-Jacques Boffa; Patrick Fievet; Laurent Mesnard; Johann Morelle; Pierre Ronco; Karine Dahan
Journal:  Kidney Int Rep       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.